Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384363 | 0.89 | CXCR3 (0.39) | PTGDR2PTGS1CYP2C9CXCR3POLB | |
| SCHEMBL2385830 | 0.88 | F2RL3 (0.41) | PTGDR2PTGS1CXCR3KDM4EF2RL3 | |
| SCHEMBL2383728 | 0.84 | F2RL3 (0.40) | PTGDR2PTGS1CYP2C9CXCR3KDM4E | |
| SCHEMBL2382190 | 0.84 | F2RL3 (0.46) | KDM4EHSD17B10F2RL3SMN1; SMN2 | |
| SCHEMBL2385228 | 0.81 | PTGDR2 (0.42) | PTGDR2CXCR3KDM4EF2RL3SMN1; SMN2 | |
| SCHEMBL2381078 | 0.80 | PGR (0.41) | CYP2C9KDM4EHSD17B10F2RL3SMN1; SMN2 | |
| SCHEMBL4771698 | 0.80 | F2RL3 (0.40) | CXCR3KDM4EL3MBTL1F2RL3SMN1; SMN2 | |
| SCHEMBL2385112 | 0.76 | P2RX3 (0.39) | F2RL3 | |
| SCHEMBL1339573 | 0.75 | KDM4E (0.46) | KDM4EHSD17B10 | |
| SCHEMBL1336873 | 0.73 | GABRA1 (0.42) | KDM4EHSD17B10F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | PTGDR2 49/4885PTGS1 1209/4885CYP2C9 544/4885 |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | PNPO, PLPBP, DPYD | PTGDR2 75/4885PTGS1 2145/4885CYP2C9 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.